William Blair Analysts Decrease Earnings Estimates for SERA

Sera Prognostics, Inc. (NASDAQ:SERA) – Investment analysts at William Blair lowered their Q3 2025 earnings estimates for shares of Sera Prognostics in a research note issued on Monday, February 3rd. William Blair analyst A. Brackmann now forecasts that the company will earn ($0.24) per share for the quarter, down from their previous estimate of ($0.23). The consensus estimate for Sera Prognostics’ current full-year earnings is ($0.96) per share. William Blair also issued estimates for Sera Prognostics’ Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.98) EPS.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter in the prior year, the firm posted ($0.23) earnings per share.

Sera Prognostics Price Performance

Shares of SERA stock opened at $4.71 on Wednesday. Sera Prognostics has a 1-year low of $4.61 and a 1-year high of $12.35. The company has a market cap of $159.06 million, a price-to-earnings ratio of -4.76 and a beta of 0.81. The stock’s fifty day moving average price is $7.24 and its 200 day moving average price is $7.28.

Institutional Trading of Sera Prognostics

A number of hedge funds have recently modified their holdings of the stock. Quest Partners LLC raised its position in Sera Prognostics by 533.5% during the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after acquiring an additional 5,415 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Sera Prognostics during the 3rd quarter worth approximately $78,000. The Manufacturers Life Insurance Company purchased a new position in shares of Sera Prognostics during the 2nd quarter valued at approximately $68,000. Prime Capital Investment Advisors LLC purchased a new position in shares of Sera Prognostics during the 3rd quarter valued at approximately $104,000. Finally, Pallas Capital Advisors LLC acquired a new position in shares of Sera Prognostics in the 4th quarter valued at $113,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

Insiders Place Their Bets

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 12,075 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $7.32, for a total transaction of $88,389.00. Following the sale, the chief executive officer now directly owns 819,758 shares of the company’s stock, valued at approximately $6,000,628.56. This trade represents a 1.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joshua Phillips sold 12,710 shares of Sera Prognostics stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $7.40, for a total value of $94,054.00. Following the transaction, the director now owns 5 shares of the company’s stock, valued at $37. The trade was a 99.96 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 93,215 shares of company stock valued at $666,835. Insiders own 15.80% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.